^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Ovarian Serous Adenocarcinoma

    Related cancers:
    10h
    Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System. (PubMed, BMC Cancer)
    One in three women showed a pathogenic mutation, demonstrating a significant prevalence of germline mutations in this sample. Additionally, the small sample revealed an interesting number of mutations, indicating the need to explore more regions of the country.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation
    13h
    A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary (clinicaltrials.gov)
    P1/2, N=14, Terminated, Avenge Bio, Inc | Trial completion date: Aug 2026 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2024; Sponsor Decision to close study
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    AVB-001
    2d
    CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2024 --> Aug 2024
    Enrollment open • Trial primary completion date • Circulating tumor DNA
    4d
    Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer. (PubMed, Cancer Lett)
    More significantly, intratumoral delivery of UCA1-specific siRNAs inhibits the growth of cisplatin-refractory ovarian cancer xenografts, demonstrating the therapeutic potential of targeting LPAR-UCA1-let-7 axis in ovarian cancer. Thus, our results identify LPAR-UCA1-let-7 axis as a novel avenue for targeted treatment strategies.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    cisplatin
    6d
    Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy. (PubMed, Drug Resist Updat)
    Collectively, our findings suggest a model wherein Syk fosters therapeutic resistance by promoting DNA resection and HR through a hitherto uncharacterized ATM-Syk-CtIP pathway. Moreover, Syk emerges as a promising tumor-specific target to sensitize Syk-expressing tumors to PARP inhibitors, radiation and other DNA-targeted therapies.
    Journal • PARP Biomarker
    |
    SYK (Spleen tyrosine kinase)
    6d
    VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma. (PubMed, Front Oncol)
    This correlation may refer to the role of VISTA as a receptor in the TCs and not in the immune cells. Thus, targeting combination therapy blocking VISTA, CTLA4, and PD1 could be a novel and attractive strategy for HGSOC treatment, considering the ambivalent role of VISTA in the HGSOC tumor cells.
    Journal • PD(L)-1 Biomarker • IO biomarker • Tumor cell
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • VSIR (V-Set Immunoregulatory Receptor)
    |
    PD-L1 expression • PD-1 expression • CTLA4 expression
    7d
    A Study of Sovilnesib in Subjects With Ovarian Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, Volastra Therapeutics, Inc. | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1
    Enrollment open • Phase classification • Metastases
    |
    sovilnesib (AMG 650)
    7d
    A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance. (PubMed, Int J Mol Sci)
    Furthermore, DNA damage tolerance and cellular stress management pathways were enriched. This novel, syngeneic model provides a valuable platform for investigating the underlying mechanisms of cisplatin resistance in a clinically relevant context, contributing to the development of targeted therapies tailored to combat resistance in stem-like ovarian cancer.
    Preclinical • Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation
    |
    cisplatin
    7d
    MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer. (PubMed, Int J Mol Sci)
    High expression of miR-1206, miR-10a-5p, miR-141-3p, and miR-96-5p correlated with poor prognosis in OC patients according to the KM plotter database. These nine miRNAs could be used as targets for therapy and as markers of cisplatin response.
    Preclinical • Journal
    |
    PTEN (Phosphatase and tensin homolog) • MIR200C (MicroRNA 200c) • MIR96 (MicroRNA 96) • MIR141 (MicroRNA 141) • MIR182 (MicroRNA 182) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a)
    |
    ZEB1 expression • miR-141 expression
    |
    cisplatin
    7d
    Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing. (PubMed, Eur J Med Res)
    This comprehensive analysis of somatic mutations in HGSOC provides insight into potential therapeutic targets and molecular pathways for targeted interventions. AP3S1 was identified as being a key player in tumor immunity and prognosis, thus providing new perspectives for personalized treatment strategies. The findings of this study contribute to the understanding of HGSOC pathogenesis and provide a foundation for improved outcomes in patients with this aggressive disease.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation • BRCA1 mutation • BRCA2 mutation + TP53 mutation
    9d
    Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses. (PubMed, Br J Cancer)
    Our preclinical studies of BA in advanced ovarian cancer models support further testing of BA as an improved immunotherapy option for patients with advanced ovarian cancer.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • IFNG expression
    |
    bintrafusp alfa (M7824)
    10d
    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) (clinicaltrials.gov)
    P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • olvimulogene nanivacirepvec (GL-ONC1)
    10d
    OU-SCC-PTC-001: Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P1, N=27, Completed, University of Oklahoma | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024
    Trial completion • Trial completion date
    |
    carboplatin • paclitaxel • unesbulin (BMIi-1)
    10d
    N6-methyadenosine modified KREMEN2 promotes tumorigenesis and malignant progression of high grade serous ovarian cancer. (PubMed, Lab Invest)
    In addition, we found that FTO-mediated m6A modification of KREMEN2 mRNA was recognized and stabilized by the m6A reader IGF2BP1 rather than IGF2BP2 or IGF2BP3. This study highlights the m6A modification of KREMEN2 and extends the importance of RNA epigenetics in HGSOC.
    Journal
    |
    IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3)
    |
    FTO expression • FTO overexpression
    11d
    Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer. (PubMed, Cancers (Basel))
    However, it did not outperform single-agent navitoclax. With optimization, this drug combination could provide a new therapeutic option for ovarian cancer and warrants further preclinical investigation.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    navitoclax (ABT 263)
    12d
    SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma. (PubMed, J Gynecol Oncol)
    SLAMF7 is expressed in the interstitial components of clinical OC tissue, and higher SLAMF7 expression indicated a favorable prognosis for patients with OC. Additionally, SLAMF7 is involved in T-cell immune infiltration in OC.
    Journal • IO biomarker
    |
    CD22 (CD22 Molecule) • CD36 (thrombospondin receptor) • FCER2 (Fc Fragment Of IgE Receptor II) • SLAMF7 (SLAM Family Member 7)
    13d
    Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 mutation • TP53 expression
    |
    adavosertib (AZD1775)
    13d
    MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=46, Terminated, University of Pennsylvania | N=18 --> 46 | Trial completion date: Oct 2038 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2038 --> Mar 2024; This study was halted prematurely due to recruitment barriers
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    cyclophosphamide
    14d
    Unveiling the role of tRNA-derived small RNAs in MAPK signaling pathway: implications for cancer and beyond. (PubMed, Front Genet)
    Downregulation of tsRNA-1018, tsRNA-3045b, tsRNA-5021a and tsRNA-1020 affected the expression of MAPK pathway, thereby improving Acute lung injury (ALI). This review comprehensively dissects tsRNA roles in MAPK signaling across cancers and other diseases, illuminating a novel avenue for translational medical exploration.
    Review • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • PRKCA (Protein Kinase C Alpha)
    |
    MYC expression • CCND1 expression
    14d
    Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer. (PubMed, J Immunother Cancer)
    We have identified a novel antitumor mechanism underlying PARG inhibition beyond its primary antitumor effects through blocking DDR in ovarian cancer. Furthermore, targeting PARG activates antitumor immune responses, thereby potentially increasing response rates to immunotherapy in patients with ovarian cancer.
    Journal • BRCA Biomarker • IO biomarker • Tumor cell
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    STAT3 mutation
    17d
    Sialyl-Tn serves as a potential therapeutic target for ovarian cancer. (PubMed, J Ovarian Res)
    Our preclinical data support the concept that an anti-STn-ADC may be a viable option for treating patients with elevated STn levels. Moreover, our STn-based ELISA could complement IHC in identifying patients with whom an anti-STn-based strategy might be more effective.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    18d
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers. (PubMed, Br J Cancer)
    This study demonstrated that targeting both the ER and the ER signaling activity related MEK pathway may aid the development of endocrine therapy strategies for personalized medicine.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER expression
    18d
    Structural elucidation and prognostic relevance of 297-11A-sulfated glycans in ovarian carcinoma. (PubMed, Lab Invest)
    Of clinical importance is that expression of 297-11A-sulfated glycans correlated with shorter progression-free survival in patients. Thus, 297-11A-sulfated glycans may serve as a predictor of ovarian carcinoma recurrence.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    19d
    Deletion of PTP4A3 phosphatase in high grade serous ovarian cancer cells decreases tumorigenicity and produces marked changes in intracellular signaling pathways and cytokine release. (PubMed, J Pharmacol Exp Ther)
    Marked differences in intracellular protein phosphorylation and cytokine release were seen. The newly developed PTP4A3 knockout cells should provide useful tools to probe the role of PTP4A3 phosphatase in ovarian cancer cell survival, tumorigenicity and cell signaling.
    Journal
    |
    IL6 (Interleukin 6) • PTP4A3 (Protein Tyrosine Phosphatase 4A3)
    19d
    Management challenges in low-grade serous ovarian cancer with a BRCA mutation. (PubMed, Int J Gynecol Cancer)
    No abstract available
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    19d
    Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer. (PubMed, Cancer Causes Control)
    Tumors from parous women with HGSC expressed PR more often than tumors from nulliparous women, indicating that pregnancies might possibly have a long-lasting impact on ovarian cancer development.
    Journal
    |
    PGR (Progesterone receptor) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PGR positive • PGR expression
    20d
    SGNB6A-001: A Study of SGN-B6A in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=824, Recruiting, Seagen Inc. | Trial completion date: Oct 2024 --> Oct 2028 | Trial primary completion date: Jul 2024 --> Nov 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (SGN-B6A)
    20d
    Identification of long noncoding RNAs downregulated specifically in ovarian high-grade serous carcinoma. (PubMed, Reprod Med Biol)
    We identified eleven lncRNAs that were specifically downregulated in HGSC. Of these, CBR3-AS1, NBR2, and ADAMTS9-AS2 had unique functions in the malignant behaviors of HGSC.
    Journal
    |
    CBR3 (Carbonyl Reductase 3) • CBR3-AS1 (CBR3 Antisense RNA 1) • HAND2-AS1 (HAND2 Antisense RNA 1) • MEG3 (Maternally Expressed 3) • NBR2 (Neighbor Of BRCA1 LncRNA) • XIST (X Inactive Specific Transcript)
    20d
    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. (PubMed, Nat Commun)
    Subsequent preclinical experiments demonstrated significant cytotoxicity of POLA1 silencing in combination with CHK1i in platinum-resistant HGSOC cell line models. Therefore, POLA1 expression may be predictive for CHK1i resistance, and the concurrent POLA1 inhibition may improve the efficacy of CHK1i monotherapy in this hard-to-treat population, deserving further investigation.
    P2 data • Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • POLA1 (DNA Polymerase Alpha 1)
    |
    BRCA wild-type
    |
    prexasertib (ACR-368)
    22d
    Proteomic profiles of peritoneal-derived small extracellular vesicles correlate with outcome in ovarian cancer patients. (PubMed, J Clin Invest)
    In addition, unsupervised analysis of PFD-sEVs proteomic profiles in high-grade serous ovarian carcinomas (HGSOC) revealed two clusters with different outcomes in terms of overall survival. In conclusion, comprehensive characterization of the PFD-sEVs content provided a prognostic value with potential implications in HGSOC clinical management.
    Journal
    |
    S100A4 (S100 calcium binding protein A4)
    23d
    Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology. (PubMed, Int J Mol Sci)
    However, the relationship between TIMP3 and endometrial cancers remains unclear. TIMP3 may be a useful biomarker for gynaecological cancers and is a potential target for future cancer therapy.
    Review • Journal
    |
    TIMP3 (TIMP Metallopeptidase Inhibitor 3)
    |
    HAVCR2 expression
    23d
    Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women. (PubMed, Int J Mol Sci)
    Our data indicate that BRCA1 and MGMT epimutations significantly contribute to the development of breast cancer and ovarian cancer in Saudi cancer patients. These blood-based biomarkers could help identify female patients at high risk of developing TNBC and HGSOC at an early age.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    BRCA1 mutation
    24d
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma. (PubMed, Gynecol Oncol)
    TP53 hotspot mutations or high pathogenicity scores were not associated with platinum resistance or refractory disease. Contrary to prior studies, TP53 gain-of-function mutations were not associated with platinum resistance. Estimation of TP53 gain-of-function effect using missense mutation phenotype scores was not associated with platinum resistance. The polymorphic nature of TP53 mutations may be too complex to demonstrate effect using simple models, or response to platinum therapy may be independent of initiating TP53 mutation.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    26d
    Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. (PubMed, J Gynecol Oncol)
    CRS may not be a prognostic factor in patients with BRCA mutations and those receiving frontline maintenance therapy.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Avastin (bevacizumab)
    27d
    A Study of LY2880070 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=229, Recruiting, Esperas Pharma Inc. | Phase classification: P1b/2a --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER expression
    |
    gemcitabine • ESP-01
    27d
    Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with BRCA mutated advanced high grade serous ovarian cancer: 10 year survival analysis. (PubMed, Int J Gynecol Cancer)
    Primary cytoreductive surgery was associated with improved survival in women with stage III/IV BRCA mutated high grade serous ovarian cancers compared with neoadjuvant chemotherapy.
    Journal • BRCA Biomarker • Surgery • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    27d
    BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. (PubMed, Front Oncol)
    Importantly, forthcoming therapeutic strategies, including combination with antiangiogenics or with targeted therapies, may help us delay and overcome PARPi resistance secondary to BRCA1/2 reversion mutations. Also, progression despite PARPi therapy does not preclude PARPi rechallenge in selected patients.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    28d
    A deep learning-based assessment pipeline for intraepithelial and stromal tumor-infiltrating lymphocytes in high-grade serous ovarian carcinoma. (PubMed, Am J Pathol)
    Gene expression analysis showed that the immune-desert subgroup had lower immune cytolytic activity (CYT) and T-cell-inflamed gene-expression profile (GEP) scores, whereas immune-excluded subgroup had higher expression of interferon-γ and programmed death 1 receptor (PD-1) signaling pathway. Our established evaluation method provides detailed and comprehensive quantification of intraepithelial and stromal TILs throughout hematoxylin and eosin (H&E)-stained slides, and has potential for clinical application for personalized treatment of patients with ovarian cancer.
    Journal • Tumor-infiltrating lymphocyte • PD(L)-1 Biomarker • IO biomarker • Stroma
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    28d
    Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers. (PubMed, Clin Cancer Res)
    sWGS and targeted sequencing identified therapeutic opportunities in 75% of p53abn EC patients. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn ECs.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HRD (Homologous Recombination Deficiency) • CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • PPP2R1A (Protein Phosphatase 2 Scaffold Subunit Aalpha)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • HER-2 mutation • HRD • MYC amplification • CCNE1 amplification • HRD + BRCA1 mutation • HRD signature
    28d
    In Silico Approach to Molecular Profiling of the Transition from Ovarian Epithelial Cells to Low-Grade Serous Ovarian Tumors for Targeted Therapeutic Insights. (PubMed, Curr Issues Mol Biol)
    This research provides a valuable framework for the development of personalized therapeutic approaches in the context of LGSC, with the aim of improving patient outcomes and quality of life. Furthermore, the main goal of the current study is a preliminary study designed to generate in silico inferences, and it is also important to note that subsequent in vitro and in vivo studies will be necessary to confirm the results before considering these results as fully reliable.
    Journal
    |
    FGFR3 (Fibroblast growth factor receptor 3) • CD74 (CD74 Molecule) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • SPP1 (Secreted Phosphoprotein 1) • IGF1 (Insulin-like growth factor 1) • ITGB2 (Integrin Subunit Beta 2)
    29d
    Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. (PubMed, Nat Commun)
    Taken together, our data demonstrate that - at odds with NSCLC - HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that might be insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    30d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Suspended, Gustave Roussy, Cancer Campus, Grand Paris | N=112 --> 51 | Trial completion date: Mar 2027 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Dec 2024
    Enrollment change • Trial completion date • Trial suspension • Trial primary completion date • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)